about us
“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
November 1962
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Mathew Sargent
Mathew Sargent is Chief of Business Development at Harbinger Health where he drives growth and expansion, overseeing strategic alliances and partnerships while nurturing existing relationships for continued advancement in our industry. Matt brings more than 20 years of experience leading high-performance commercial teams and business development in oncology diagnostics. Before joining Harbinger Health, he served as Vice President of Commercial Oncology at Hologic, with responsibility for sales, commercial strategy and business development for the CLIA Oncology diagnostics service business.
Prior to Hologic’s acquisition of Biotheranostics, Matt served as the Biotheranostics Chief Commercial Officer, where he launched the Breast Cancer Index (BCI) test and led the total commercial program including Sales, Marketing, Market Access and Customer service. As the first Vice President of Oncology Sales at Caris Life Sciences, Matt built out the oncology commercial program and launched the industry’s first commercial NGS-based comprehensive genomics profiling platform. Matt’s earlier career included commercial leadership positions at Oncotech, acquired by Exiqon Diagnostics and Burleigh Instruments, acquired by EXFO Electro Optical Engineering.
Matt earned a B.S. from Cornell University in Anatomy and Animal Physiology, a M.S. in Cancer Physiology from the University of Buffalo, Roswell Park Cancer Institute Graduate Division, and his M.B.A. from Pepperdine University.
